These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34778985)

  • 1. Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.
    Sugi T; Mita M; Yasu T; Kubo K; Kushi R; Hanai H; Ohara S; Uchida T; Inoue M; Hagihara M
    J Clin Pharm Ther; 2022 Apr; 47(4):477-482. PubMed ID: 34778985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
    Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
    Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
    Sugi T; Nishigami Y; Saigo H; Hanai H; Takabatake K; Mita M; Ohara S; Ide S; Uchida T; Inoue M; Hagihara M
    Leuk Lymphoma; 2021 Jun; 62(6):1405-1410. PubMed ID: 33509006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients with Newly Diagnosed Multiple Myeloma].
    Okayama Y; Takakuwa T; Otomaru I; Horiuchi M; Miura A; Araki T; Fujitani Y; Yamamura R
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):815-819. PubMed ID: 34139730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
    Xu T; Yang Y; Li J; Xu J; Wang W; Wang Y; Maihemaiti A; Ren L; Lan T; Zhou C; Li P; Wang P; Liu P
    Ann Hematol; 2023 May; 102(5):1171-1184. PubMed ID: 36882560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
    Sugi T; Mita M; Yasu T; Ohara S; Uchida T; Inoue M; Hagihara M
    J Clin Pharm Ther; 2021 Dec; 46(6):1792-1795. PubMed ID: 33960000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
    Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
    J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
    Teitelbaum A; Ba-Mancini A; Huang H; Henk HJ
    Oncologist; 2013; 18(1):37-45. PubMed ID: 23299776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
    Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Okamura S
    Intern Med; 2015; 54(14):1711-5. PubMed ID: 26179523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma.
    Murakami S; Ri M; Ito M; Nakamura N; Kasahara S; Kitagawa J; Inagaki Y; Kuroda J; Yoshimitsu M; Okamoto A; Fukuhara N; Taji H; Iida H; Nagai H; Hanamura I; Tsujimura H; Okura M; Kurata M; Kuwatsuka Y; Atsuta Y; Iida S
    Int J Hematol; 2022 Oct; 116(4):563-569. PubMed ID: 35699890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
    Khouri J; Faiman BM; Grabowski D; Mahfouz RZ; Khan SN; Wei W; Valent J; Dean R; Samaras C; Jha BK; Lazarus H; Campagnaro EL; Malek E; Reed J; Karam MA; Hamilton K; Fada S; Kalaycio M; Liu H; Sobecks R; Saunthararajah Y; Chew Y; Orloff M; Reu FJ
    Semin Hematol; 2021 Jan; 58(1):45-55. PubMed ID: 33509443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
    Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
    Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
    Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Management of Lenalidomide-Related Rash.
    Tinsley SM; Kurtin SE; Ridgeway JA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S64-9. PubMed ID: 26297281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
    Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.